Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE:…
SAN FRANCISCO, July 11, 2023 (GLOBE NEWSWIRE) — Artificial intelligence and machine learning innovator McClintock…
SAN FRANCISCO, July 11, 2023 (GLOBE NEWSWIRE) — Artificial intelligence and machine learning innovator McClintock…
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to…
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to…
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months…
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months…
Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in Canada…
Composition of matter and use patent for Versamune® in combination with PDS0301 allowed in Canada…
Former CEO and Founder, Esther Alegria Remains on Executive Team Focused on Driving Research &…
Former CEO and Founder, Esther Alegria Remains on Executive Team Focused on Driving Research &…
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN…
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN…
Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase…
Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase…
Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of…
Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of…
Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study…